ATE183195T1 - Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren - Google Patents

Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren

Info

Publication number
ATE183195T1
ATE183195T1 AT95914752T AT95914752T ATE183195T1 AT E183195 T1 ATE183195 T1 AT E183195T1 AT 95914752 T AT95914752 T AT 95914752T AT 95914752 T AT95914752 T AT 95914752T AT E183195 T1 ATE183195 T1 AT E183195T1
Authority
AT
Austria
Prior art keywords
hla
molecules
complex
derived peptides
isolated mage
Prior art date
Application number
AT95914752T
Other languages
English (en)
Inventor
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Katharina Fleischauer
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE183195T1 publication Critical patent/ATE183195T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95914752T 1994-03-24 1995-03-21 Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren ATE183195T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/217,187 US5554506A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Publications (1)

Publication Number Publication Date
ATE183195T1 true ATE183195T1 (de) 1999-08-15

Family

ID=22810011

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914752T ATE183195T1 (de) 1994-03-24 1995-03-21 Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren

Country Status (16)

Country Link
US (3) US5554506A (de)
EP (1) EP0759032B1 (de)
JP (1) JP3451356B2 (de)
CN (1) CN1142177C (de)
AT (1) ATE183195T1 (de)
AU (1) AU682956B2 (de)
CA (1) CA2186005A1 (de)
DE (1) DE69511399T2 (de)
DK (1) DK0759032T3 (de)
ES (1) ES2135051T3 (de)
FI (1) FI963781A7 (de)
GR (1) GR3031811T3 (de)
NZ (1) NZ283543A (de)
TW (1) TW496875B (de)
WO (1) WO1995025739A1 (de)
ZA (1) ZA952376B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6087441A (en) * 1997-02-05 2000-07-11 Ludwig Institute For Cancer Research Structurally modified peptides that are resistant to peptidase degradation
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6326200B1 (en) 1997-06-23 2001-12-04 Ludwig Institute For Cancer Research Isolated nona-and decapeptides which bind to HLA molecules, and the use thereof
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
AU2001229681A1 (en) * 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
DE60238864D1 (de) * 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
CN103242428B (zh) * 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
EP2480572B1 (de) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralisierende antikörper gegen hiv-1 und ihre verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Also Published As

Publication number Publication date
JP3451356B2 (ja) 2003-09-29
AU682956B2 (en) 1997-10-23
JPH10500667A (ja) 1998-01-20
GR3031811T3 (en) 2000-02-29
FI963781L (fi) 1996-09-23
US5554506A (en) 1996-09-10
AU2187095A (en) 1995-10-09
US6353089B1 (en) 2002-03-05
EP0759032B1 (de) 1999-08-11
CN1151167A (zh) 1997-06-04
EP0759032A1 (de) 1997-02-26
NZ283543A (en) 1998-04-27
CN1142177C (zh) 2004-03-17
DK0759032T3 (da) 1999-12-27
WO1995025739A1 (en) 1995-09-28
DE69511399D1 (de) 1999-09-16
FI963781A0 (fi) 1996-09-23
DE69511399T2 (de) 2000-05-11
EP0759032A4 (de) 1997-04-09
CA2186005A1 (en) 1995-09-28
ES2135051T3 (es) 1999-10-16
TW496875B (en) 2002-08-01
US6019987A (en) 2000-02-01
ZA952376B (en) 1995-12-14
FI963781A7 (fi) 1996-09-23

Similar Documents

Publication Publication Date Title
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
ATE201214T1 (de) Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung
FI950887A0 (fi) MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
ATE267254T1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
NO874796L (no) Hybridomcellelinjer som produserer monoklonale antistoffer som reagerer med mucinepitoper.
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
BR9707379A (pt) Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo
FI954536A0 (fi) Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö
EP0739350A4 (de) Fas-antigenbindender ligand
HUP0000318A2 (hu) Tumorvakcina és eljárás előállítására
IL111105A (en) Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
AU5008785A (en) Process for synthesising peptides
IL147810A0 (en) Antitumor antibodies, proteins and uses thereof
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
UA66753C2 (en) Immunostimulator and method for its production
YARILIN et al. Comparative Immunochemical Characterization of Transplantation Antigens of Some Mouse Organs
NZ329694A (en) Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer